Cargando…

Combining hypoxia-activated prodrugs and radiotherapy in silico: Impact of treatment scheduling and the intra-tumoural oxygen landscape

Hypoxia-activated prodrugs (HAPs) present a conceptually elegant approach to not only overcome, but better yet, exploit intra-tumoural hypoxia. Despite being successful in vitro and in vivo, HAPs are yet to achieve successful results in clinical settings. It has been hypothesised that this lack of c...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hamis, Sara, Kohandel, Mohammad, Dubois, Ludwig J., Yaromina, Ala, Lambin, Philippe, Powathil, Gibin G.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Public Library of Science 2020
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425994/ https://www.ncbi.nlm.nih.gov/pubmed/32745136 http://dx.doi.org/10.1371/journal.pcbi.1008041

Ejemplares similares

Predicting and elucidating the post-printing behavior of 3D printed cancer cells in hydrogel structures by integrating in-vitro and in-silico experiments
por: Mohammadrezaei, Dorsa, et al.
Publicado: (2023)

Modeling the Spatial Distribution of Chronic Tumor Hypoxia: Implications for Experimental and Clinical Studies
por: Powathil, Gibin, et al.
Publicado: (2012)

Hypoxia-activated prodrugs and (lack of) clinical progress: The need for hypoxia-based biomarker patient selection in phase III clinical trials
por: Spiegelberg, Linda, et al.
Publicado: (2019)

In silico analysis of hypoxia activated prodrugs in combination with anti angiogenic therapy through nanocell delivery
por: Meaney, Cameron, et al.
Publicado: (2020)

Charged Particle and Conventional Radiotherapy: Current Implications as Partner for Immunotherapy
por: Marcus, Damiënne, et al.
Publicado: (2021)

Selectively Targeting Tumor Hypoxia With the Hypoxia-Activated Prodrug CP-506
por: van der Wiel, Alexander M.A., et al.
Publicado: (2021)

Targeting Cellular DNA Damage Responses in Cancer: An In Vitro-Calibrated Agent-Based Model Simulating Monolayer and Spheroid Treatment Responses to ATR-Inhibiting Drugs
por: Hamis, Sara, et al.
Publicado: (2021)

Towards Predicting the Response of a Solid Tumour to Chemotherapy and Radiotherapy Treatments: Clinical Insights from a Computational Model
por: Powathil, Gibin G., et al.
Publicado: (2013)

The immunocytokine L19-IL2: An interplay between radiotherapy and long-lasting systemic anti-tumour immune responses
por: Rekers, Nicolle H., et al.
Publicado: (2018)

Combining radiotherapy with immunotherapy: the past, the present and the future
por: Van Limbergen, Evert J, et al.
Publicado: (2017)

Hypoxia-Activated Prodrug Derivatives of Carbonic Anhydrase Inhibitors in Benzenesulfonamide Series: Synthesis and Biological Evaluation
por: Anduran, Emilie, et al.
Publicado: (2020)

Prognostic Role of Hypoxia-Inducible Factor-2α Tumor Cell Expression in Cancer Patients: A Meta-Analysis
por: Moreno Roig, Eloy, et al.
Publicado: (2018)

Prognostic Significance of Carbonic Anhydrase IX Expression in Cancer Patients: A Meta-Analysis
por: van Kuijk, Simon J. A., et al.
Publicado: (2016)

Hypoxia PET Imaging with [18F]-HX4—A Promising Next-Generation Tracer
por: Sanduleanu, Sebastian, et al.
Publicado: (2020)

Polyphenols as Potential Protectors against Radiation-Induced Adverse Effects in Patients with Thoracic Cancer
por: Prades-Sagarra, Èlia, et al.
Publicado: (2023)

The hypoxia-activated prodrug evofosfamide in combination with multiple regimens of radiotherapy
por: Nytko, Katarzyna J., et al.
Publicado: (2017)

Targeting the hypoxic fraction of tumours using hypoxia-activated prodrugs
por: Phillips, Roger M.
Publicado: (2016)

Novel fluorinated carbonic anhydrase IX inhibitors reduce hypoxia-induced acidification and clonogenic survival of cancer cells
por: Kazokaitė, Justina, et al.
Publicado: (2018)

Releasing the brakes of tumor immunity with anti-PD-L1 and pushing its accelerator with L19–IL2 cures poorly immunogenic tumors when combined with radiotherapy
por: Olivo Pimentel, Veronica, et al.
Publicado: (2021)

Predicting the Tumour Response to Radiation by Modelling the Five Rs of Radiotherapy Using PET Images
por: Hami, Rihab, et al.
Publicado: (2023)

A phase 1 ‘window-of-opportunity’ trial testing evofosfamide (TH-302), a tumour-selective hypoxia-activated cytotoxic prodrug, with preoperative chemoradiotherapy in oesophageal adenocarcinoma patients
por: Larue, Ruben T. H. M., et al.
Publicado: (2016)

In vivo optical imaging of MMP2 immuno protein antibody: tumor uptake is associated with MMP2 activity
por: Panth, Kranthi Marella, et al.
Publicado: (2016)

BAY 87–2243, a novel inhibitor of hypoxia-induced gene activation, improves local tumor control after fractionated irradiation in a schedule-dependent manner in head and neck human xenografts
por: Helbig, Linda, et al.
Publicado: (2014)

Homologous Recombination Deficiency Scar: Mutations and Beyond—Implications for Precision Oncology
por: van der Wiel, Alexander M. A., et al.
Publicado: (2022)

Human fibronectin extra domain B as a biomarker for targeted therapy in cancer
por: Lieverse, Relinde I. Y., et al.
Publicado: (2020)

From prodrug to pro-prodrug: hypoxia-sensitive antibody–drug conjugates
por: Wang, Yanming, et al.
Publicado: (2022)

Targeting Hypoxia: Hypoxia-Activated Prodrugs in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

Switching-on Prodrugs Using Radiotherapy
por: Geng, Jin, et al.
Publicado: (2021)

Evofosfamide sensitizes esophageal carcinomas to radiation without increasing normal tissue toxicity
por: Spiegelberg, Linda, et al.
Publicado: (2019)

An agent-based model for drug-radiation interactions in the tumour microenvironment: Hypoxia-activated prodrug SN30000 in multicellular tumour spheroids
por: Mao, Xinjian, et al.
Publicado: (2018)

Hypoxia-activated prodrugs and redox-responsive nanocarriers
por: Zeng, Yun, et al.
Publicado: (2018)

Nitroaromatic Hypoxia-Activated Prodrugs for Cancer Therapy
por: Denny, William A.
Publicado: (2022)

The Hypoxia-Activated Prodrug TH-302: Exploiting Hypoxia in Cancer Therapy
por: Li, Yue, et al.
Publicado: (2021)

Reinforcement learning derived chemotherapeutic schedules for robust patient-specific therapy
por: Eastman, Brydon, et al.
Publicado: (2021)

Bioreductive prodrugs as cancer therapeutics: targeting tumor hypoxia
por: Guise, Christopher P., et al.
Publicado: (2014)

Studies Towards Hypoxia-Activated Prodrugs of PARP Inhibitors
por: Dickson, Benjamin D., et al.
Publicado: (2019)

In vitro radiosensitization of breast cancer with hypoxia‐activated prodrugs
por: Aiyappa‐Maudsley, Radhika, et al.
Publicado: (2022)

Antibody-Based Imaging of Bioreductive Prodrug Release in Hypoxia
por: Tosun, Çağla, et al.
Publicado: (2023)

Long-lasting antitumor effects provided by radiotherapy combined with the immunocytokine L19-IL2
por: Rekers, Nicolle H, et al.
Publicado: (2015)

Modelling the effects of bacterial cell state and spatial location on tuberculosis treatment: Insights from a hybrid multiscale cellular automaton model
por: Bowness, Ruth, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_6is387mt1nujg3efv5dlsibdd6